OPS 2
Alternative Names: OPS-2Latest Information Update: 28 May 2024
Price :
$50 *
At a glance
- Originator Oncopeptides
- Class Antineoplastics; Peptide drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Triple negative breast cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 28 May 2024 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA
- 28 May 2024 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA